OL Oncology Letters 1792-1074 1792-1082 D.A. Spandidos 10.3892/ol.2016.4778 OL-0-0-4778 Articles Attempt towards a novel classification of triple-negative breast cancer using immunohistochemical markers LiuYan-Xi 1 WangKe-Ren 1 XingHua 1 ZhaiXu-Jie 1 WangLi-Ping 2 WangWan 1 Department of Breast Surgery, China-Japan Union Hospital of Jilin University, Changchun, Jilin 130033, P.R. China Department of Pathology, China-Japan Union Hospital of Jilin University, Changchun, Jilin 130033, P.R. China Correspondence to: Dr Wan Wang, Department of Breast Surgery, China-Japan Union Hospital of Jilin University, 126 Xiantai Blvd, Changchun, Jilin 130033, P.R. China, E-mail: wangwan0106@yahoo.com 08 2016 23 06 2016 12 2 1240 1256 05042015 24052016 Copyright: © Liu et al. 2016 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Significant efforts have been made to gain a better understanding of the heterogeneity of triple-negative breast cancers from the histological to the molecular and genomic levels. In this study, we attempted to bring forward gene expression subtypes of triple-negative breast cancer (TBNC) to the clinic, by translating gene stratification to clinically accessible immunohistochemical (IHC) classification. Using IHC analysis, we categorized 154 TBNC cases into three main subclasses. Differences in the frequencies of basic characteristics and clinicopathological parameters between the subtypes were examined using Chi-square tests. We defined three main groups among the 154 triple-negative cases. The basal-like (BL) group expressed cytokeratin (CK) 5/6 and/or CK14 (83 cases), the AR+ group demonstrated positivity for androgen receptor (18 cases), and the final group exhibited a CD44+CD24-/low phenotype (39 cases). There were three overlapping cases between the BL subgroup and the CD44+CD24-/low phenotype subgroup, and 11 unclassified cases. In this new IHC classification, three subcategories exhibited a statistical difference with regard to age, tumor size, histological grade, tumor necrosis, Ki67 labeling index, relapse-free survival, breast cancer-specific survival and response to chemotherapy. According to our definition, the BL group and CD44+CD24-/low phenotype could be observed in tumors that were not triple-negative, and BL tumors that were triple-negative demonstrated almost undistinguishable clinicopathological characteristics compared with BL tumors that were not triple-negative. The same observation was made with CD44+CD24-/low tumors that were triple-negative vs. CD44+CD24-/low tumors that were not. The AR+ group demonstrated undistinguishable clinicopathological characteristics compared with the luminal subtype. We successfully distinguished three subtypes exhibiting diverse clinicopathological and prognostic characteristics with the minimum use of IHC markers.

 triple-negative breast cancer classification clinicopathological characteristics prognosis Introduction

Triple-negative breast cancer (TNBC), an aggressive type of breast cancer, lacks effective targeted therapy due to the absence of hormone receptors and human epidermal growth factor-2 (HER2). Therefore, considerable effort has been made to identify subclasses of TNBC with distinct characteristics that may potentially be targeted in the clinic.

In 2008, Cheang et al (1) revealed that TNBC cases that positively expressed epidermal growth factor receptor (EGFR) or cytokeratin (CK) 5/6 demonstrated a shorter survival time and poorer response to chemotherapy, but might benefit from EGFR-targeted therapy (2–7). Another marker in TNBC with potential prognostic and therapeutic value, androgen receptor (AR), has drawn particular attention since 2010 (8). In recent years, studies have progressed to the molecular level. Prat et al (9) investigated the correlation between TNBC molecular subtypes and the PAM50 intrinsic subtypes as well as the claudin-low subtype. These authors observed that the majority of TNBCs were either basal-like (39 to 54%) or claudin-low (25% to 39%), followed by HER2-enriched and luminal. However, Lehmann et al (10) reported another classification based on gene expression profiles of 587 TNBCs: basal-like 1 (BL1), basal-like 2 (BL2), immunomodulatory (IM), mesenchymal (M), mesenchymal stem-like (MSL), and luminal androgen receptor (LAR). Further analysis narrowed these down to three main groups (BL, mesenchymal-like and LAR), which demonstrated different responses to cytotoxic and targeted therapies.

These apparently different classifications may be related (11). Basal-like in the PAM50 assay encompassed the TNBC BL subtypes defined by Lehmann as well as certain tumors classified as IM and M (10,12). In addition, MSL describes a similar group of claudin-low cancers while LAR shares a number of gene expression features of estrogen receptor (ER)-positive and HER2-enriched cancers (10,12). Thus, despite the lack of consensus, it appears reasonable to predict that there are three basic subtypes within TNBC (11,13–15).

Gene expression-based classification significantly changes our understanding of the heterogeneity of TNBC. However, it raises the question of how this sophisticated approach can be translated into a practical and clinically accessible diagnostic test, given that gene identification is currently not feasible for large-scale application on routine formalin-fixed paraffin-embedded clinical samples (16). In this study, we adopt the immunohistochemistry (IHC) methodology. We examined the IHC profile of 154 TNBC cases and identified three subtypes exhibiting diverse clinicopathological and prognostic characteristics with the minimum use of biomarkers.

 Patients and methods <sec> <title>Patient selection

We collected breast cancer cases with sufficient medical records from the Department of Breast Surgery, China-Japan Union Hospital of Jilin University, China, between January 2006 and November 2014. Inclusion criteria for this study were: i) female; ii) primary stage I–III invasive breast cancer; iii) no neoadjuvant chemotherapy or radiotherapy prior to surgery; iv) breast tissue samples available for study. All of the subjects underwent surgical treatment according to standard treatment protocols. Clinicopathological parameters including age, histological subtype, tumor size, histological grade, nodal status, and presence of lymphovascular invasion and tumor necrosis were noted. The histological subtype and histological grade were assessed in accordance with standard guidelines and confirmed independently by two pathologists from the Department of Pathology at the China-Japan Union Hospital of Jilin University. The median follow-up time was 68 months (range, 2 to 108 months). The study was approved by the ethics committee of Jilin University.

 Immunohistochemistry and scoring

Immunohistochemical staining was performed according to the following protocol. Sections from paraffin-embedded tissue microarrays were cut to 4 µm, deparaffinized in xylene and rehydrated through graded alcohols. Microwave epitope retrieval was performed in target retrieval pH 6.0 (Dako, Carpinteria, CA, USA) for ER and HER2, high pH target retrieval for CK5/6 (Dako), or 10 mM citrate buffer (pH 6.0) for 10 min followed by cooling for 15 min at room temperature for claudins.

The following antibodies were used: clone SP1 against ER (1:300 dilution; Dako), clone SP2 against progesterone receptor (PR; 1:250 dilution; Neomarkers, Fremont, CA, USA), clone SP3 against HER2 (1:200 dilution; Neomarkers), clone SP6 against Ki67 (1:200 dilution; Neomarkers), clone D5/16B4 against CK5/6 (1:100 dilution; M7237; Dako), clone LL002 against CK14 (1:20; NCL-LL002; Novocastra, Newcastle upon Tyne, UK), clone E30 against EGFR (1:50; M7239; Dako), clone NCH-38 against E-cadherin (1:50, Dako), clone V9 against vimentin (1:150, Dako), clone Z23.JM against claudin 3 (1:300; Invitrogen Life Technologies, Carlsbad, CA, USA), clone Ab15104 against claudin 4 (1:300, Abcam), clone Ab27287 against claudin 7 (1:400; Abcam, Cambridge, MA), clone AR27 against AR (1:100, NCL-AR-318), clone 156-3C11 against CD44 (1:100, Cell Signaling Technology, Inc., Danvers, MA, USA), and clone Ab2-SN3b against CD24 (1:100 Neomarkers).

Staining results were assessed by two pathologists in a blinded fashion. For ER, PR and AR status, stains were considered positive if at least 1% of tumor nuclei demonstrated positivity, regardless of the intensity (1 to 3+). For HER2 status, stains were considered positive if at least 30% of tumor cells exhibited a cell membrane staining score of 3+. There are no commonly accepted cut-off points reported for EGFR. Membranous EGFR staining in >1% of tumor cells was used as the definition of protein positivity according to the Dako criteria provided in the pharmDx kit instructions. For Ki67, the mean percentage of nuclear positivity was evaluated in a stepwise manner; i.e. 1, 2, 3, 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 70, 80 and 90%. For CK5/6 and CK14, staining was scored as positive when more than 10% of the tumor cells demonstrated cytoplasmic and/or membranous staining. E-cadherin expression was analyzed semi-quantitatively according to the percentage of cells demonstrating membrane positivity: 0, 0–10%; 1+, 10–30%; 2+, 30–70%; 3+, > 70%. E-cadherin expression was considered positive when scores were ≥2 and negative when scores were ≤1. Any distinct positive staining of the tumor cytoplasm in cancer cells with the vimentin antibody was regarded as positive vimentin expression. Claudin immunoreactivity was assessed based on a combined score of the extension and intensity of membrane expression. The extension was registered as the percentage of positive cells for claudins: 0, 0%; 1+, <25%; 2+, 25–50%; 3+, >50%. The intensity of membrane immunostaining was graded as: 0 (negative); 1 (weak); 2 (moderate); 3 (strong). The two scores were multiplied to give an overall score of 0–9, of which 0 was considered negative, 1–2 was considered weak, 3–6 moderate, and 9 strong staining. Negative and weak expression was considered as low, while moderate and strong were considered high. Tumors with low expression of all three claudins were defined as claudin-low. For CD44 and CD24, stains were scored positive when more than 10% of the tumor cells exhibited membranous staining. We considered a tumor to have a cancer stem cell (CSC) phenotype when the frequency of CD44+CD24-/low cells was more than 10%, as previously described in other studies (17,18). Any discordant scores were reviewed together by the two scorers to obtain a consensus.

 Definition of breast cancer subtypes by IHC

Identifying subgroups of TNBC is of significance for a better understanding of this complex disease. By drawing on the work of Prat et al (9,13) and Lehmann et al (10,12) on gene expression subtypes, we attempted for the first time to classify TNBC into three subsets using IHC markers. Our main aim was to seek IHC surrogates that potentially identify the main three gene expression subtypes. Here are certain noteworthy points from the studies of Prat et al and Lehmann et al: i) TNBC subtypes defined by Lehmann differentially correlate with the PAM50 intrinsic subtypes (12,13). BL1, BL2, IM and M cases are primarily composed of the BL intrinsic subtype (99%, 95%, 84% and 97%, respectively), while ~50% of MSL cases and none of LAR cases have the BL intrinsic subtype (12). Therefore, the vast majority of non-basal TNBCs are MSL and LAR tumors. In addition, BL1, BL2, IM and M subtypes express higher levels of basal cytokeratin expression (i.e., CK5/6 and CK14), while tumors in the MSL category exhibit significantly lower basal cytokeratin expression and LAR tumors lack basal cytokeratin expression (10,12). ii) LAR shares a number of gene expression features of ER+ and HER2-enriched cancers (10). AR protein is highly expressed within the LAR subgroup, on average >10-fold higher than all other subtypes (10). iii) MSL is characterized by enrichment for gene expression patterns associated with epithelial-to-mesenchymal (ETM) transition (10,12,19). A portion of the MSL subtypes also are enriched for the CSC-like phenotype (10,12,19), and exhibit low expression of tight junction proteins including claudin 3, 4 and 7 (10,12,19), consistent with a group of cancers previously described as claudin-low (9). iv) The three main subtypes (BL, mesenchymal-like and LAR) defined by Lehmann et al (10) are concordant with the three main groups previously identified by Prat et al (BL, claudin-low and luminal/HER2-enriched) (13) and by Neve et al (20) and Kao et al (21), based upon cell lines alone (basal A, associated with the ETS pathway and BRCA1 signatures and resembling BL tumors; basal B, exhibiting mesenchymal and stem/progenitor cell characteristics; and luminal, exhibiting an ER signature and resembling luminal A/B tumors).

Together, it appears feasible to translate the gene expression subtypes into three IHC subtypes. Based on the first point above, triple-negative cases which also positively express either CK5/6 or CK14 are referred to as the ‘BL’ group in this article. Therefore, the BL subgroup in this article likely encompasses the BL1, BL2, IM and M subtypes and a small proportion of the MSL tumors that express basal cytokeratin. Based on the second point, triple-negative cases which also positively express AR are referred to as the AR+ group. However, selecting IHC marker panels to define the third group is relatively challenging. According to the classification defined by Lehmann et al, the majority of the third group consists of MSL tumors that lack basal cytokeratin expression (12), whereas according to Prat et al (13), the third group should be claudin-low. Although MSL and claudin-low share certain similar features, they are not synonymous. All MSL tumors are associated with EMT transition (10,11), which is characterized by downregulation of E-cadherin and occludin and induction of mesenchymal marker proteins including vimentin and fibronectin (22–25), while only a portion of MSL cases are claudin-low, enriched in CSC-like features with an absence of claudin proteins. Therefore, in order to distinguish the most appropriate IHC surrogates for the third group, we explored the ETM phenotype (evaluating vimentin and E-cadherin expression), CSC-like phenotype (analyzing CD44 and CD24 expression), and claudin 3, 4 and 7 expression in all triple-negative cases, and then defined the third group as vimentin+ and E-cadherin-; CD44+CD24-/low phenotype; low expression of all three claudins, respectively. Vimentin and E-cadherin are well-established and widely accepted as markers for EMT (20–23), while CD44+CD24-/low is a known marker for the CSC-like phenotype (9,21,26,27).

 Statistical analysis

Differences in the frequencies of basic characteristics and clinicopathological parameters among breast cancer subtypes were examined using Chi-square tests, or Fisher's exact test in the case of less than five expected cases. Relapse-free survival (RFS) was defined as the time from the date of diagnosis to the date of relapse of breast cancer, including locoregional recurrence and/or distant metastasis. Breast cancer-specific survival (BCSS) was defined as the date of a patient's diagnosis of breast cancer until mortality. Survival times were censored if the primary or underlying cause of mortality was not breast cancer, or if the patient was still alive on December 30, 2014 (the date when the outcome data were collected). Survival curves were obtained using the Kaplan-Meier method and differences in survival among the breast cancer subtypes were assessed by the log-rank test. Prognostic analyses used the Cox regression method. Univariate analyses tested classical clinicopathological features: age (>50 vs. ≤50), pathological tumor size (pT2-3 vs. pT1), lymph node status (positive vs. negative), histological grade (2 or 3 vs. 1), necrosis (marked vs. minimal or absent), Ki67 (>30% vs. ≤30%), adjuvant chemotherapy (performed vs. not performed). The findings were analyzed using SPSS statistical software for Windows, version 18 (SPSS, Inc., Chicago, IL, USA. All statistical tests were two-sided, and P<0.05 was considered to indicate a statistically significant difference.

 Results <sec> <title>Patient characteristics

There were a total of 2407 breast cancer patients receiving surgery at the China-Japan Union Hospital of Jilin University between January 2006 and November 2014. Among these, 1646 cases that had informative IHC results were included in the study. The median age at diagnosis in the study population was 54 years (range, 23–87 years). Mastectomy was performed in 78.3% of cases (1289/1646), and 21.7% (357/1646) underwent breast conserving surgery. Following surgery, 82.6% (1360/1646) received adjuvant chemotherapy. The remaining 286 (17.4%) patients did not receive any adjuvant systemic chemotherapy. The median follow-up time was 68 months (range, 2 to 108 months). Of the 1646 patients, 154 had triple-negative breast cancer (TNBC). The clinicopathological characteristics and IHC profiles of the TNBC cases and other types of breast cancer (non-TNBC) are presented in Table I. The Chi-square test revealed a statistically significant difference in tumor size, histological grade, tumor necrosis and Ki67 labeling index between TNBC and non-TNBC patients. The two groups also differed in the levels of AR, CK5/6, CK14, EGFR, E-cadherin, vimentin, claudin 3, 4 and 7 expression and CD44+CD24-/low phenotype (Fig. 1). TNBCs had a statistically larger percentage of tumors that were positive for CK5/6 (57.8%), CK14 (39.6%), EGFR (59.0%), vimentin (44.2%) and CD44+CD24-/low phenotype (27.3%) compared with non-TNBCs (2.2%, 2.1%, 6.8%, 7.2% and 2.4%, respectively). AR, E-cadherin, and claudins 3, 4 and 7 staining was greater in non-TNBCs (83.2%, 71.7%, 97.6%, 97.2% and 97.4%, respectively), whereas the positivity for these five markers in TNBCs was 11.7%, 43.5%, 68.2%, 74.0% and 72.7% (P=0.000).

 New IHC classification of TNBC

As described in the Patients and methods section, we defined triple-negative cases which also positively expressed either CK5/6 or CK14 as the BL group, triple-negative cases which also positively expressed AR as the AR+ group, and respectively defined the third group as vimentin+ and E-cadherin-; CD44+CD24-/low phenotype; low expression of claudins 3, 4 and 7. A comparison of these three different classifications is shown in Fig. 2. A lower level of overlap was observed between the BL group and the third group when the third group was defined as CD44+CD24-/low phenotype, and the proportion of unclassified cases was also relatively smaller in this classification model. Therefore, the three subtypes of TNBC designated in this study are the BL group (83 cases), AR+ group (18 cases), and CD44+CD24-/low phenotype (39 cases). Eleven cases that were unclassified and three cases that overlapped between the BL group and CD44+CD24-/low phenotype were excluded in the following study.

The clinicopathological characteristics of each TNBC subtype are shown in Table II. When a difference among the three groups was detected, multiple comparison was carried out to assess where the difference lies. The Chi-square test revealed that the three subcategories exhibited significantly different characteristics in terms of age, tumor size, histological grade, presence/absence of tumor necrosis and Ki67 labeling index. Multiple comparison further demonstrated that the three subtypes differed significantly from each other in histological grade and tumor necrosis, but not in age, tumor size or Ki67 labeling index. The histological grade of the CD44+CD24-/low subtype was often grade 3 (53.8%) or grade 2 (28.2%), which was lower than tumors in the BL group (grade 3, 81.9%; grade 2, 14.4%), and higher than those in the AR+ group (grade 3, 16.7%; grade 2, 33.3%). A total of 38.5% of CD44+CD24-/low subtype cases demonstrated marked tumor necrosis, a percentage intermediate between that of the BL group (57.8%) and the AR+ group (11.1%).

As for age and tumor size, although the Chi-square test revealed a statistically significant difference among the three subcategories, multiple comparison revealed that only the difference between the BL group and AR+ group was significant. Patients with AR+ tumors were older than patients with BL tumors (>50 years, 66.7% vs. 37.3%; multiple comparison test, P=0.0226). A total of 55.5% of AR+ tumors measured ≤2 cm (pT1) while 28.9% of BL tumors were pT1 (multiple comparison test, P=0.0301). In the multiple comparison test, although the CD44+CD24-/low subtype did not reveal distinct characteristics in age and tumor size when separately compared with the BL group and AR+ group, the percentage of patients older than 50 years (53.8%) and the percentage of pT1 tumors (46.2%) were intermediate between the BL group and AR+ group.

As for the Ki67 labeling index, multiple comparison revealed that a significant difference existed between AR+ group and BL group (P<0.001), and also between AR+ group and CD44+CD24−/low group (P=0.0389). However, BL group and CD44+CD24−/low group did not differ in Ki67 (P=0.1463). A total of 22.2% of AR+ tumors had a Ki67 labeling index >30%, which indicated a less proliferative subtype compared with the BL group (65.1%) and CD44+CD24-/low subtype (51.3%).

 RFS and BCSS by IHC subtypes

The RFS time of TNBC patients ranged from 4 to 102 months with a median time of 61 months. During the study period, 50 out of 154 (32.5%) TNBC patients experienced local recurrence and/or metastasis. Among these 50 cases, 32 (64%) were in the BL group, 3 (6%) were in the AR+ group, 13 (26%) were in the CD44+CD24-/low subtype, and 2 (4%) were in the unclassified group. The hazard ratio (HR) and 95% confidence interval (CI) of RFS for several basic characteristics by TNBC subtype are shown in Table III. Survival analyses are demonstrated in Fig. 3A. Larger tumor size, positive lymph node status and higher histological grade significantly increased the recurrence risk of TNBC tumors. All of the three subgroups maintained this feature of TNBCs. However, marked tumor necrosis, which could increase the recurrence risk of TNBC, AR+ and CD44+CD24-/low subgroups, did not significantly affect the RFS within the BL subgroup. A higher Ki67 labeling index (>30%) only increased the recurrence risk of AR+ tumors.

The BCSS time ranged from 2 to 108 months with a median time of 68 months. Thirty-six of the 154 (23.4%) TNBC patients succumbed to breast cancer, 12 patients succumbed to other diseases and 106 were alive at the end of the study. The HR and 95% CI for BCSS are shown in Table IV, and survival analyses are shown in Fig. 3B. The three subtypes did not exhibit notable differences either in the RFS or BCSS time (log-rank P=0.053 for RFS, log-rank P=0.126 for BCSS). Multiple comparison only detected a difference between the AR+ and BL group (log-rank P=0.020 for RFS, log-rank P=0.044 for BCSS). Tumor size, lymph node involvement, histological grade and tumor necrosis were significant prognostic factors in the analysis with all cases of TNBC, and with each subtype of TNBC. In the AR+ group, a higher Ki67 labeling index (>30%) also demonstrated prognostic value.

 Chemotherapy effects on the subtypes

The univariate analyses above tested the prognostic value of adjuvant chemotherapy in all TNBC cases and the different subcategories, and it was revealed that only the BL group received a significant RFS and BCSS benefit from adjuvant chemotherapy (RFS: HR, 0.26; 95% CI, 0.12–0.71; P=0.004; BCSS: HR, 0.18; 95% CI, 0.09–0.65; P<0.001), whereas adjuvant chemotherapy was not associated with significantly prolonged RFS and BCSS in other subtypes and TNBCs as a whole. In order to investigate whether the three subtypes responded differently to chemotherapy, we further divided each subtype into two groups in the survival analysis depending on use of adjuvant chemotherapy. Among the 83 BL patients, 31 were treated with anthracycline-based chemotherapy (19 with doxorubicin/cyclophophamide and 12 with fluorouracil/doxorubicin/cyclophosphamide), 38 were treated with nonanthracycline-based chemotherapy (cyclophosphamide, methotrexate and fluorouracil), and 14 received no adjuvant systemic therapy. Among the 18 AR+ patients, 9 received anthracycline-based chemotherapy (3 doxorubicin/cyclophosphamide and 6 fluorouracil/doxorubicin/cyclophosphamide), 5 received nonanthracycline-based chemotherapy, and 4 received no adjuvant systemic therapy. Among the 39 CD44+CD24-/low patients, 21 received anthracycline-based chemotherapy (14 doxorubicin/cyclophosphamide and 7 fluorouracil/doxorubicin/cyclophosphamide), 8 received nonanthracycline-based chemotherapy, and 10 received no adjuvant systemic therapy.

The survival analysis revealed that patients in the BL group without chemotherapy had the shortest RFS and BCSS times and demonstrated a significant survival gain following chemotherapy (P=0.003 for RFS, P<0.001 for BCSS; Fig. 3C-F). Conversely, AR+ and CD44+CD24-/low patients did not demonstrate a chemotherapy benefit in either RFS or BCSS. However, the results require careful interpretation due to the small numbers. There was no difference in RFS and BCSS among the three subclasses; however, after we categorized each subclass according to chemotherapy, a notable distinction emerged (log-rank P=0.003 for RFS, log-rank P=0.008 for BCSS).

In the multiple variate analyses (adjusted for age, tumor size, histological grade, lymph node status and tumor necrosis), the BL group demonstrated a significantly poorer survival, with a HR of 2.98 vs. the luminal A cohort (95% CI, 1.38–6.10; P<0.001; Table VA), a higher HR of 3.81 vs. luminal A in the cases without chemotherapy (95% CI, 1.98–6.32; P<0.001; Table VC), and a relatively lower HR of 1.93 vs. luminal A in the cases with chemotherapy (95% CI, 1.21–4.09, P=0.028; Table VB). This confirmed the survival gain of adjuvant chemotherapy in BL patients. In contrast, the AR+ group did not exhibit a poorer survival vs. the luminal A cohort (HR, 1.38; 95% CI, 0.67–2.14; P=0.204), and the HR was 1.13 (95% CI, 0.62–2.89; P=0.574) in the cases with chemotherapy, and 1.53 (95% CI, 0.68–1.98; P=0.124) in the cases without chemotherapy. The decrease in HR owing to chemotherapy in the AR+ group (from 1.53 to 1.13) was far less significant than that in the BL group (from 3.81 to 1.93). In the CD44+CD24-/low group, there was an increase rather than a decrease in HR in the subset of patients who received chemotherapy (HR, 2.30; 95% CI, 0.95–2.84; P=0.003) compared with those who did not (HR, 1.72; 95% CI, 0.88–2.74; P=0.092). We cannot assume that chemotherapy increases the risk of mortality in CD44+CD24-/low phenotype TNBCs, but the results did reveal a notable trait of CD44+CD24-/low tumors in that they do not respond to chemotherapy as well as the BL subtype.

 Correlation between IHC TNBC subtypes and subtypes in non-TNBC

CK5/6+, CK14+ and CD44+CD24-/low phenotype were not only observed in TNBCs, but also in non-TNBC cases. Of the 1492 non-TNBCs, 34 cases positively expressed either CK5/6 or CK14, and they are referred to as BL/non-TN in this study. Accordingly, the 36 cases that had the CD44+CD24-/low phenotype are referred to as CD44+CD24-/low/non-TN. An issue that cannot be ignored is the correlation between BL tumors that are TNBC (BL/TN) and BL/non-TN, and CD44+CD24-/low tumors that are TNBC (CD44+CD24-/low/TN) and CD44+CD24-/low/non-TN. To be specific, we take the BL subtype as an example. BL was defined as positive for CK5/6 or CK14, and BL/TN has certain distinct features as shown above, including younger age, higher histological grade and poorer prognosis. Therefore, through a comparison of clinicopathological characteristics between BL/TN and BL/non-TN we could observe whether these features of CK5/6+ and/or CK14+ tumors would be retained regardless of their clinical ER, PR and HER2 status, and particularly their TN status. The results of comparison may indicate whether BL/TN cases possess these traits more due to their BL status (i.e. their positivity for CK5/6 or CK14) or more due to their TN status (i.e. their triple-negative status). Thus, it may provide us with a better understanding of the intrinsic quality of these TNBC subtypes. A comparison of clinicopathological characteristics between BL/TN and BL/non-TN, and CD44+CD24-/low/TN and CD44+CD24-/low/non-TN is shown in Table V. As for the AR+ group, we did not compare AR+ tumors that were triple-negative with those that were not. As mentioned in the Patients and methods section, several previous studies (10,13,20,21) have made the same observation that TN tumors with high AR protein and/or gene expression (or LAR, according to Lehmann et al (10,12) were usually identified as HER2 or luminal by PAM50 intrinsic subtyping, and their levels of AR expression resembled the levels observed in HER2 and ER-positive tumors that were not TN. However, the authors had divergent opinions on percentage that the HER2 and luminal groups accounted for. According to Mayer et al (19), the LAR subtype is classified as HER2 (74.3%) and luminal (14.3%); however, based on the statistics of Lehmann et al (10) 82% of LAR cases were luminal (either luminal A or B). Therefore, we separately compared the AR+ group of TNBC with the luminal subtype [including luminal A (ER+ and/or PR+, HER2−) and luminal B (ER+ and/or PR+, HER2+)] and HER2 subtype (ER−, PR−, HER2+) that were not TNBC. Based on the data from Table VI, BL/TN cases demonstrated almost undistinguishable clinicopathological characteristics compared with BL/non-TN cases, as did CD44+CD24-/low/TN cases compared with CD44+CD24-/low/non-TN cases. The features of the AR+ group resembled those of the non-TNBC luminal group rather than those of HER2. Next, a survival analysis was performed and differences in RFS and BCSS were compared between BL/TN and BL/non-TN, CD44+CD24-/low/TN and CD44+CD24-/low/non-TN, and the AR+ and luminal group (Fig. 4). Multiple comparison revealed no significant difference between BL/TN and BL/non-TN (log-rank P=0.9 for RFS, log-rank P=0.9 for BCSS), CD44+CD24-/low/TN and CD44+CD24-/low/non-TN (log-rank P=0.6 for RFS, log-rank P=0.5 for BCSS), or the AR+ group and luminal group (log-rank P=0.7 for RFS, log-rank P=0.8 for BCSS).

 Discussion

In this study, a large number of clinical breast cancer cases were evaluated and the following observations concerning TN breast cancers were made: i) TN disease is a heterogeneous clinical entity composed of three main IHC subtypes, with the BL tumor type predominating (>50%); ii) The three subcategories demonstrated a statistically significant difference with regard to age, tumor size, histological grade, tumor necrosis, Ki67 labeling index and response to chemotherapy; iii) Basal-like tumors that are TN exhibit almost undistinguishable clinicopathological characteristics compared with BL tumors that are non-TN. The same applies with CD44+CD24-/low/TN vs. CD44+CD24-/low/non-TN and AR+/TN vs. luminal/non-TN.

Our study is a preliminary attempt to use gene expression subtypes in a practical and clinically accessible diagnostic test. We use IHC methodology to observe how TNBC can be broken down into components. This novel IHC classification system was based on the perspectives of Lehmann et al (10,12,19), who identified six subtypes (BL1, BL2, IM, M, MSL and LAR), and Prat et al (13), who contended that the three main subtypes were BL, claudin-low and luminal/HER2-enriched. These two seemingly different classifications are correlated; for instance, LAR shares a number of gene expression features of luminal and HER2-enriched cancers, as illustrated in Patients and methods. However, in the definition of Prat et al (13), the identification of luminal/TN tumors, HER2/TN tumors might appear at first glance to be counterintuitive, and an explanation is required with regard to the discrepancy between gene expression and IHC-based assays. One possibility is the false positivity or false negativity of the IHC-based assays in determining hormone receptor or HER2 status (28). Another possibility is that the pathology and gene expression data could have been obtained from two different areas of the same tumor (i.e., intratumor heterogeneity) (29). The most plausible explanation is that gene expression measures a large number of related genes, compared with the three individual pathology-based biomarkers that define TN disease (13). Thus, multigene expression data using tens to hundreds of genes might better capture the true biological profile of a given tumor compared with three or four individual biomarkers (30). For example, a TN tumor that has low levels of ESR1 and PGR, and consequently is ER- and PR- by IHC, might be identified as luminal due to the high expression of other luminal-related genes (i.e., AR, GATA3 and/or FOXA1) and the low expression of basal- and proliferation-related genes. Another example comes from the identification of HER2-enriched/TN tumors that do not amplify ERBB2, some of which might be driven by high EGFR (13).

In previous studies, BL breast cancers accounted for up to 15% of all breast cancers (31,32). Most of them used the definition of Nielsen et al (31), which is positive staining for CK5/6 or EGFR (31). In this study, the proportion of BL breast cancers was 7.11% (53.9% of TNBCs). Of a total of 117 BL breast cancers, 70.94% (83 of 117) were TNBCs, and 29.06% (34 of 117) were non-TNBCs. We used basal markers CK5/6 and CK14 instead of CK5/6 and EGFR for four reasons: i) Based on the recent progress in TNBC gene subtyping by Prat et al (13), expression of EGFR was observed to be significantly increased in HER2-enriched/TN tumors compared with HER2-enriched/non-TN tumors, thus suggesting that certain HER2-enriched tumors, which are at gene level in line with HER2-enriched tumors but are HER2- by IHC, may be driven by EGFR as discussed above. This implies that EGFR expression is not confined to BL cancers (10,19). ii) The EGFR gene is not enriched in all BL tumors but in the BL2 subtype alone (10). It is also enriched in a minority of mesenchymal subtypes (10). iii) Not only has specificity of EGFR for defining BL breast cancers become lower than it used to be when subtyping was not as comprehensive as today, but also the prognostic value of EGFR was challenged. In the study of Choi et al (33), CK5/6 was a poor prognostic marker whereas EGFR was not. 4) According to Won et al (34), in a survey of IHC biomarkers for BL breast cancer against a gene expression profile gold standard, CK14 was the most specific (specificity 100%) among the 46 biomarkers surveyed. If we used CK5/6 and EGFR, the proportion of BL breast cancers increased to 14.12%, and accounted for 65.6% of TNBCs, which was similar to the figure of 15% obtained in the previous study. However, this might obscure certain significant information since EGFR+ tumors comprise part of the AR+ group. Indeed, 10 out of 18 AR+ TNBCs demonstrated weak or strong positivity for EGFR.

AR+ tumors constitute a distinct subgroup of TNBC. A total of 11.7% of TNBCs were AR+ in this study. Among 22 studies summarized in the article of Safarpour et al (35), the proportion of tumors with positive AR among TNBCs ranged from 6.6% to 75%. Among six studies which had used the most recent ASCO/CAP guidelines (1% and more) for ER, PR and AR positivity, the expression rate of AR ranged from 12.7% to 41.4%. This group has certain valuable clinicopathological features including smaller tumor size, higher median age, lower histological grade, higher percentage of apocrine morphology, lower proliferation index (measured by Ki67) and statistically longer disease-free survival and overall survival (8,36–48). Our study also arrived at similar conclusions. In terms of IHC features, it is noteworthy that none of the AR+ tumors in our study were positive for CK5/6 or CK14, and due to the relatively small series of analyzed samples this may be coincidental; however, it is in accordance with the study of Lehmann et al that LAR cancers lacked expression of basal cytokeratins. So far, no organization has recommended AR assessment for breast cancers; however, we support routine assessment of AR at least for TNBCs considering the predictive value of AR in TNBC.

AR+ and BL are two subtypes that have received significant interest and are relatively well analyzed. However, emerging data imply that TN disease is a broad and diverse category for which additional subclassifications are required. One of the contributions of this study is that, for the first time, we distinguished a subgroup of TNBC as the CD44+CD24-/low phenotype using IHC markers, and the overlap between this third group and BL and AR+ was low (3 and 0 cases, respectively). CD44+CD24-/low is a marker of breast stem cells and tumor-initiating cells and is observed to be exclusively enriched in claudin-low subtype (26,27). There are also other features in the claudin-low subtype, for instance, low gene expression of tight junction proteins claudin 3, 4 and 7 and E-cadherin (9,26,27,49,50). However, when we used negativity for claudins 3, 4 and 7 to define the third group, there were 24 cases, a relatively large proportion, that could not be classified. This is possibly due to the fact that negativity for all claudins is a much stricter restriction compared with CD44+CD24-/low. In addition, a study of Prat et al (9), a researcher who contributed significantly to our knowledge of the claudin-low subtype of breast cancer, revealed that BL tumors did not demonstrate significantly lower expression of CD24 as a group. This crucial distinction may explain the lowest overlap between the BL group and CD44+CD24-/low group. In another classification where vimentin+ and E-cadherin- were used, the highest overlap was observed. In fact, undifferentiated levels of mesenchymal (vimentin) markers exist not only within the claudin-low subtype, but also in BL breast cancers, and no statistically significant difference was observed between claudin-low and BL tumors (9). We defined a number of differences between the CD44+CD24-/low subtype and the other groups. Clinicopathological characteristics including histological grade and tumor necrosis were different from the AR+ as well as the BL group. The age at diagnosis of this group was older, the tumor size was smaller, and the Ki67 labeling index was lower than that of the BL group. The two groups demonstrated an unfavorable clinical outcome; however, the CD44+CD24-/low group did not benefit from adjuvant chemotherapy to the extent that the BL group did. Sabatier et al (51) also made similar findings in their study of clinical, pathological and prognostic characterization of claudin-low breast cancers, revealing that the percentage of patients older than 50, the percentage of grade 3 claudin-low tumors, the percentage of tumors measuring 2 cm or less, and the 5-year disease-free survival rate were all intermediate between that of the highly proliferative subtypes (BL and HER2-enriched) and that of less proliferative ones (luminal A and normal).

Without chemotherapy, the BL subcategory had the poorest prognosis in terms of RFS and BCSS. Notably, the BL group demonstrated a distinct clinical benefit with standard adjuvant chemotherapy. Conversely, adjuvant chemotherapy demonstrated little clinical benefit for the AR+ and CD44+CD24-/low subclasses. Masuda et al (52) performed a retrospective analysis on 130 TNBC cases treated with neoadjuvant adriamycin/cytoxan/taxol-containing chemotherapy, and subtype-specific responses differed substantially, with the BL1 subtype achieving the highest pathological complete remission rate (52%), and the BL2, LAR and MSL subtypes having the lowest responses (0%, 10% and 23%, respectively). In accordance with the work of Masuda et al (52), Mayer et al (19) observed a similar distribution of subtype-specific differences in survival. These findings should guide differential use of chemotherapy-based regimens and instruct clinical trials to investigate targeted therapies.

In summary, TNBC is a relatively uncommon, notably aggressive disease, and there is a major requirement to better decipher the heterogeneity of TNBC in order to tackle the challenges in combatting this disease. New therapeutic strategies for TNBC are emerging since gene subtyping was identified. Therefore, our future clinical trial design for TNBC intends to focus on continued efforts to translate genetic approaches into clinical utility, to develop a more standard IHC classification of TNBC. Our aim is to provide a labor- and timesaving method for clinicians to distinguish the subtypes of TNBC in their daily work and, in the near future, select a more appropriate personalized therapy based on these subtypes.

 Acknowledgements

This study was supported by the National Natural Science Foundation of China (grant no. 81472343).

 References CheangMCVoducDBajdikCLeungSMcKinneySChiaSKPerouCMNielsenTOBasal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotypeClin Cancer Res1413681376200810.1158/1078-0432.CCR-07-165818316557 AguiarFNMendesHNCirqueiraCSBacchiCECarvalhoFMBasal cytokeratin as a potential marker of low risk of invasion in ductal carcinoma in situClinics (Sao Paulo)68638643201310.6061/clinics/2013(05)01023778411 FadareOWangSAHileetoDThe expression of cytokeratin 5/6 in invasive lobular carcinoma of the breast: evidence of a basal-like subset?Hum Pathol39331336200810.1016/j.humpath.2007.07.01418261623 LeeHJSeoANKimEJJangMHKimYJKimJHKimSWRyuHSParkIAImSAPrognostic and predictive values of EGFR overexpression and EGFR copy number alteration in HER2-positive breast cancerBr J Cancer112103111201510.1038/bjc.2014.55625349977 ParkHSJangMHKimEJKimHJLeeHJKimYJKimJHKangEKimSWKimIAParkSYHigh EGFR gene copy number predicts poor outcome in triple-negative breast cancerMod Pathol2712121222201410.1038/modpathol.2013.25124406864 RakhaEAEl-SayedMEGreenARLeeAHRobertsonJFEllisIOPrognostic markers in triple-negative breast cancerCancer1092532200710.1002/cncr.2238117146782 SoodNNigamJSCorrelation of CK5 and EGFR with clinicopathological profile of triple-negative breast cancerPatholog Res Int2014141864201425400978 NiemeierLADabbsDJBeriwalSStriebelJMBhargavaRAndrogen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiationMod Pathol23205212201010.1038/modpathol.2009.15919898421 PratAParkerJSKarginovaOFanCLivasyCHerschkowitzJIHeXPerouCMPhenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancerBreast Cancer Res12R68201010.1186/bcr263520813035 LehmannBDBauerJAChenXSandersMEChakravarthyABShyrYPietenpolJAIdentification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapiesJ Clin Invest12127502767201110.1172/JCI4501421633166 TurnerNCReis-FilhoJSTackling the diversity of triple-negative breast cancerClin Cancer Res1963806388201310.1158/1078-0432.CCR-13-091524298068 LehmannBDPietenpolJAIdentification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypesJ Pathol232142150201410.1002/path.428024114677 PratAAdamoBCheangMCAndersCKCareyLAPerouCMMolecular characterization of basal-like and non-basal-like triple-negative breast cancerOncologist18123133201310.1634/theoncologist.2012-039723404817 AbramsonVGLehmannBDBallingerTJPietenpolJASubtyping of triple-negative breast cancer: implications for therapyCancer121816201510.1002/cncr.2891425043972 SchmadekaRHarmonBESinghMTriple-negative breast carcinoma: current and emerging conceptsAm J Clin Pathol141462477201410.1309/AJCPQN8GZ8SILKGN24619745 ChooJRNielsenTOBiomarkers for basal-like breast cancerCancers (Basel)210401065201010.3390/cancers202104024281106 RicardoSVieiraAFGerhardRLeitãoDPintoRCameselle-TeijeiroJFMilaneziFSchmittFParedesJBreast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtypeJ Clin Pathol64937946201110.1136/jcp.2011.09045621680574 MylonaEGiannopoulouIFasomytakisENomikosAMagkouCBakarakosPNakopoulouLThe clinicopathologic and prognostic significance of CD44+/CD24(−/low) and CD44−/CD24+ tumor cells in invasive breast carcinomasHum Pathol3910961102200810.1016/j.humpath.2007.12.00318495204 MayerIAAbramsonVGLehmannBDPietenpolJANew strategies for triple-negative breast cancer - deciphering the heterogeneityClin Cancer Res20782790201410.1158/1078-0432.CCR-13-058324536073 NeveRMChinKFridlyandJYehJBaehnerFLFevrTClarkLBayaniNCoppeJPTongFA collection of breast cancer cell lines for the study of functionally distinct cancer subtypesCancer Cell10515527200610.1016/j.ccr.2006.10.00817157791 KaoJSalariKBocanegraMChoiYLGirardLGandhiJKweiKAHernandez-BoussardTWangPGazdarAFMolecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discoveryPLoS One4e6146200910.1371/journal.pone.000614619582160 LiuTZhangXShangMZhangYXiaBNiuMLiuYPangDDysregulated expression of Slug, vimentin and E-cadherin correlates with poor clinical outcome in patients with basal-like breast cancerJ Surg Oncol107188194201310.1002/jso.2324022886823 LeeJHahmERMarcusAISinghSVWithaferin A inhibits experimental epithelial-mesenchymal transition in MCF-10A cells and suppresses vimentin protein level in vivo in breast tumorsMol Carcinog54417429201510.1002/mc.2211024293234 RitoMSchmittFPintoAEAndréSFibromatosis-like metaplastic carcinoma of the breast has a claudin-low immunohistochemical phenotypeVirchows Arch465185191201410.1007/s00428-014-1603-924903673 ZhangYToyKAKleerCGMetaplastic breast carcinomas are enriched in markers of tumor-initiating cells and epithelial to mesenchymal transitionMod Pathol25178184201222080057 GiatromanolakiASivridisEFiskaAKoukourakisMIThe CD44+/CD24- phenotype relates to ‘triple-negative’ state and unfavorable prognosis in breast cancer patientsMed Oncol28745752201110.1007/s12032-010-9530-320405247 HonethGBendahlPORingnerMRingnérMSaalLHGruvberger-SaalSKLövgrenKGrabauDFernöMBorgAHegardtCThe CD44+/CD24-phenotype is enriched in basal-like breast tumorsBreast Cancer Res10R53200810.1186/bcr210818559090 HammondMEHayesDFWolffACManguPBTeminSAmerican Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancerJ Oncol Pract6195197201010.1200/JOP.77700321037871 BarryWTKernagisDNDressmanHKGriffisRJHunterJDOlsonJAMarksJRGinsburgGSMarcomPKNevinsJRIntratumor heterogeneity and precision of microarray-based predictors of breast cancer biology and clinical outcomeJ Clin Oncol2821982206201010.1200/JCO.2009.26.724520368555 PratAParkerJSFanCPerouCMPAM50 assay and the three-gene model for identifying the major and clinically relevant molecular subtypes of breast cancerBreast Cancer Res Treat135301306201210.1007/s10549-012-2143-022752290 NielsenTOHsuFDJensenKCheangMKaracaGHuZHernandez-BoussardTLivasyCCowanDDresslerLImmunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinomaClin Cancer Res1053675374200410.1158/1078-0432.CCR-04-022015328174 BadveSDabbsDJSchnittSJBaehnerFLDeckerTEusebiVFoxSBIchiharaSJacquemierJLakhaniSRBasal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologistsMod Pathol24157167201110.1038/modpathol.2010.20021076464 ChoiYLOhEParkSKimYParkYHSongKChoEYHongYCChoiJSLeeJETriple-negative, basal-like and quintuple-negative breast cancers: better prediction model for survivalBMC Cancer10507201010.1186/1471-2407-10-50720860845 WonJRGaoDChowCChengJLauSYEllisMJPerouCMBernardPSNielsenTOA survey of immunohistochemical biomarkers for basal-like breast cancer against a gene expression profile gold standardMod Pathol2614381450201310.1038/modpathol.2013.9723702728 SafarpourDPakneshanSTavassoliFAAndrogen receptor (AR) expression in 400 breast carcinomas: is routine AR assessment justified?Am J Cancer Res4353368201425057438 McNamaraKMYodaTMikiYChanplakornNWongwaisayawanSIncharoenPKongdanYWangLTakagiKMayuTAndrogenic pathway in triple negative invasive ductal tumors: its correlation with tumor cell proliferationCancer Sci104639646201310.1111/cas.1212123373898 TsutsumiYApocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinomaJpn J Clin Oncol42375386201210.1093/jjco/hys03422450930 ThikeAAYong-ZhengChong LCheokPYLiHHWai-CheongYip GHuatBay BTseGMIqbalJTanPHLoss of androgen receptor expression predicts early recurrence in triple-negative and basal-like breast cancerMod Pathol27352360201423929266 TsangJYNiYBChanSKShaoMMLawBKTanPHTseGMAndrogen receptor expression shows distinctive significance in ER positive and negative breast cancersAnn Surg Oncol2122182228201410.1245/s10434-014-3629-224639191 PistelliMCaramantiMBiscottiTSantinelliAPagliacciADe LisaMBallatoreZRidolfiFMaccaroniEBracciRAndrogen receptor expression in early triple-negative breast cancer: clinical significance and prognostic associationsCancers (Basel)613511362201410.3390/cancers603135124978437 McNamaraKMYodaTTakagiKMikiYSuzukiTSasanoHAndrogen receptor in triple negative breast cancerJ Steroid Biochem Mol Biol1336676201310.1016/j.jsbmb.2012.08.00722982153 GaspariniPFassanMCascioneLGulerGBalciSIrkkanCPaisieCLovatFMorrisonCZhangJAndrogen receptor status is a prognostic marker in non-basal triple negative breast cancers and determines novel therapeutic optionsPLoS One9e88525201410.1371/journal.pone.008852524505496 LoiblSMüllerBMvon MinckwitzGSchwabeMRollerMDarb-EsfahaniSAtasevenBdu BoisAFissler-EckhoffAGerberBAndrogen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapyBreast Cancer Res Treat130477487201110.1007/s10549-011-1715-821837479 MicelloDMarandoASahnaneNRivaCCapellaCSessaFAndrogen receptor is frequently expressed in HER2-positive, ER/PR-negative breast cancersVirchows Arch457467476201010.1007/s00428-010-0964-y20809337 OgawaYHaiEMatsumotoKIkedaKTokunagaSNagaharaHSakuraiKInoueTNishiguchiYAndrogen receptor expression in breast cancer: relationship with clinicopathological factors and biomarkersInt J Clin Oncol13431435200810.1007/s10147-008-0770-618946753 WitzelIGraeserMKarnTSchmidtMWirtzRSchützeDRauschAJänickeFMilde-LangoschKMüllerVAndrogen receptor expression is a predictive marker in chemotherapy-treated patients with endocrine receptor-positive primary breast cancersJ Cancer Res Clin Oncol139809816201310.1007/s00432-013-1382-823392859 TangDXuSZhangQZhaoWThe expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancerMed Oncol29526533201210.1007/s12032-011-9948-221519872 HuRDawoodSHolmesMDCollinsLCSchnittSJColeKMarottiJDHankinsonSEColditzGATamimiRMAndrogen receptor expression and breast cancer survival in postmenopausal womenClin Cancer Res1718671874201110.1158/1078-0432.CCR-10-202121325075 LuSSinghKMangraySTavaresRNobleLResnickMBYakirevichEClaudin expression in high-grade invasive ductal carcinoma of the breast: correlation with the molecular subtypeMod Pathol26485495201310.1038/modpathol.2012.18723222490 GerhardRRicardoSAlbergariaAGomesMSilvaARLogulloÂFCameselle-TeijeiroJFParedesJSchmittFImmunohistochemical features of claudin-low intrinsic subtype in metaplastic breast carcinomasBreast21354360201210.1016/j.breast.2012.03.00122464177 SabatierRGuilleAAdelaideJChaffanetMViensPBirnbaumDBertucciFFinettiPClaudin-low breast cancers: clinical, pathological, molecular and prognostic characterizationMol Cancer13228201410.1186/1476-4598-13-22825277734 MasudaHBaggerlyKAWangYZhangYGonzalez-AnguloAMMeric-BernstamFValeroVLehmannBDPietenpolJAHortobagyiGNDifferential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypesClin Cancer Res1955335540201310.1158/1078-0432.CCR-13-079923948975

Representative hematoxylin and eosin staining of immunohistochemical biomarkers. Magnification, ×200. CK, cytokeratin; E-cad, E-cadherin; CLDN, claudin; AR, androgen receptor; EGFR, epidermal growth factor receptor.

Comparison of three different classifications. (A) The third group is defined as positive for epithelial-to-mesenchymal transition markers vimentin+ and E-cadherin-. (B) The third group is defined as claudin-low: low expression of claudin 3, 4 and 7 (C). The third group is defined as CD44+CD24−/low phenotype. AR, androgen receptor; BL, basal-like; EMT, epithelial-to-mesenchymal transition.

Kaplan-Meier curves of relapse-free and breast cancer-specific survival. (A,C,E) Relapse-free survival according to three immunohistochemistry-based subtypes of triple-negative breast cancer. (B, D and E) Breast cancer-specific survival according to three immunohistochemistry-based subtypes of triple-negative breast cancer. (A and B) all cases combined; (C and D) Cases receiving chemotherapy; (E and F) cases without chemotherapy. AR, androgen receptor; BL, basal-like.

Comparison of relapse-free survival and breast cancer-specific survival between triple-negative (TN) subtypes and non-TN breast cancer subtypes. (A) Relapse-free survival of TN and non-TN subtypes (B). Breast cancer-specific survival in TN and non-TN subtypes. AR, androgen receptor; BL, basal-like.

Clinicopathological characteristics of TNBC and non-TNBC patients.

Characteristics TNBC n=154 Non-TNBC n=1492 P-value
Age 0.649
  ≤50   85   852
  >50   69   640
Family history of breast cancer 0.131
  No 141 1411
  Yes   13     81
Histological type
  Invasive ductal carcinoma   93 1082
  Invasive lobular carcinoma 5   143
  Medullary carcinoma   13     82
  Metaplastic carcinoma   12     78
  Apocrine carcinoma   13     78
  Others 6     29
Pathological tumor size 0.002
  pT1   58   792
  pT2-3   96   700
Histological grade <0.001
  1   23   228
  2   34   943
  3   97   321
Pathological axillary lymph 0.326
node status
  Negative   91   820
  Positive   63   672
Lymphovascular invasion 0.707
  Absent 116 1103
  Present   38   389
Necrosis <0.001
  Minimal or absent   89 1368
  Marked   65   124
Ki67 <0.001
  ≤30%   72 1125
  >30%   82   367
AR <0.001
  Negative 136   251
  Positive   18 1241
CK5/6 <0.001
  Negative   65 1459
  Positive   89   33
CK14 <0.001
  Negative   93 1461
  Positive   61   31
EGFR <0.001
  Negative   94 1390
  Positive   60   102
E-cadherin <0.001
  Negative   87   422
  Positive   67 1070
Vimentin <0.001
  Negative   86 1385
  Positive   68   107
Claudin 3 <0.001
  Negative   49   36
  Positive 105 1456
Claudin 4 <0.001
  Negative   40   42
  Positive 114 1450
Claudin 7 <0.001
  Negative   42     39
  Positive 112 1453
CD44+CD24−/low <0.001
  No 112 1456
  Yes   42     36
RFS event
  No 104 1208
  Yes   50   284
Chemotherapy
  No   31   255
  Yes 123 1237
Mean survival time 86.3 98.7
  (95% CI) (79.7–93.1) (81.2–114.5)

TNBC, triple-negative breast cancer; AR, androgen receptor; CK, cytokeratin; EGFR, epidermal growth factor receptor; RFS, relapse free survival; CI, confidence interval.

Clinicopathological characteristics of triple-negative breast cancer immunohistochemical subtypes.

Characteristics Basal-like n=83 AR+n=18 CD44+CD24−/low n=39 P-value
Age 0.038
  ≤50 52   6a 18
  >0 31 12 21
Family history of breast cancer 0.839
  No 76 17 35
  Yes   7   1   4
Histological type
  Invasive ductal carcinoma 63   6 14
  Invasive lobular carcinoma   2   1   1
  Medullary carcinoma 11   0   2
  Metaplastic carcinoma   3   0 19
  Apocrine carcinoma   2 11   0
  Others   2   0   3
Pathological tumor size 0.041
  pT1 24 10a 18
  pT2-3 59   8 21
Histological grade <0.001
  1   3   9a,b   7a,b
  2 12   6 11
  3 68   3 21
Pathological axillary lymph node status 0.734
  Negative 47 12 23
  Positive 36   6 16
Lymphovascular invasion 0.174
  Absent 63 16 26
  Present 20   2 13
Necrosis <0.001
  Minimal or absent 35 16a,b 24a,b
  Marked 48   2 15
Ki67 0.003
  ≤30% 29 14a,b 19a,b
  <30% 54   4 20
EGFR 0.006
  Negative 34   8 30a,b
  Positive 41   6   9
E-cadherin <0.001
  Negative 38   4 37a,b
  Positive 45 14   2
Vimentin <0.001
  Negative 55 15   4a,b
  Positive 28   3 35
Claudin 3 <0.001
  Negative 10   2 36a,b
  Positive 73 16   3
Claudin 4 <0.001
  Negative   9   1   29a,b
  Positive 74 17 10
Claudin 7 <0.001
  Negative 11   1   28a,b
  Positive 72 17 11
Chemotherapy   0.512
  No 14   4 10
  Yes 69 14 29
RFS event
  No 51 15 26
  Yes 32   3 13
Mean survival time 75.8 96.3 84.7
  (95% CI) (59.9–88.4) (84.0–105.7) (73.4–94.2)

Compared with basal-like, P<0.05 [AR+ vs. basal-like, CD44+CD24−/low vs. basal-like).

Compared with AR+, P<0.05 [CD44+CD24−/low vs. AR+]. AR, androgen receptor; EGFR, epidermal growth factor receptor; RFS, relapse free survival; CI, confidence interval.

Hazard ratios of triple-negative breast cancer relapse-free survival for several basic characteristics by immunohistochemistry subtypes.

TNBC subtypes
TNBC n=154 Basal-like n=154 AR+n=154 CD44+CD24−/low n=154
Variables HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value
Age 1.000 1.000 1.000 1.000
  ≤50 1.00 1.00 1.00 1.00
  >50 0.88 (0.51–1.52) 0.72 (0.48–1.39) 1.06 (0.78–1.43) 0.92 (0.63–1.5)
Pathological tumor size 0.012 0.032 0.002 0.019
  pT1 1.00 1.00 1.00 1.00
  pT2-3 2.63 (1.54–3.92) 2.26 (1.32–3.49) 3.08 (1.60–4.93) 2.52 (1.22–3.85)
Lymph node status 0.003 0.024 0.001 0.014
  Negative 1.00 1.00 1.00 1.00
  Positive 2.86 (1.62–4.54) 2.41 (1.32–3.54) 3.13 (1.87–4.98) 2.60 (1.43–3.87)
Histological grade 1.000 1.000 0.048 1.000
  1 1.00 1.00 1.00 1.00
  2 1.06 (0.53–2.24) 1.02 (0.43–2.65) 1.26 (1.09–2.87) 1.03 (0.83–1.86)
  3 4,89 (2.37–8.65) <0.001 3.58 (2.79–6.94) <0.001 5.19 (2.46–9.12) <0.001 4.12 (2.03–7.45) <0.001
Necrosis 0.034 0.193 0.004 0.028
  Minimal or absent 1.00 1.00 1.00 1.00
  Marked 2.45 (1.14–3.96) 1.52 (1.06–3.34) 3.06 (1.65–4.12) 2.52 (1.21–3.84)
Ki67 1.000 1.000 0.046 1.000
  ≤30% 1.00 1.00 1.00 1.00
  >30% 1.07 (0.56–1.74) 0.88 (0.54–1.45) 1.64 (1.08–2.90) 1.03 (0.84–1.79)
Adjuvant chemotherapy 1.000 0.004 0.942 0.246
  No 1.00 1.00 1.00 1.00
  Yes 0.61 (0.32–1.34) 0.26 (0.12–0.71) 0.89 (0.64–1.35) 2.15 (0.73–6.32)

TNBC, triple-negative breast cancer; AR, androgen receptor; HR, hazard ratio; CI, confidence interval.

Hazard ratios of breast cancer-specific survival in triple-negative breast cancer for several basic characteristics by immunohistochemistry subtypes.

TNBC subtypes
TNBC n=154 Basal-like n=83 AR+n=18 CD44+CD24−/low n=39
Variables HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value
Age   1.000   1.000   1.000   1.000
  ≤50 1.00 1.00 1.00 1.00
  >50 1.06 (0.52–1.62) 0.81 (0.38–1.54) 1.10 (0.86–1.52) 0.96 (0.58–1.46)
Pathological <0.001   0.016 <0.001   0.010
  pT1 1.00 1.00 1.00 1.00
  pT2-3 2.87 (1.64–4.26) 2.44 (1.54–3.98) 3.46 (1.87–5.65) 2.61 (1.31–3.92)
Lymph node status <0.001   0.012 <0.001 <0.001
  Negative 1.00 1.00 1.00 1.00
  Positive 3.14 (1.81–5.96) 2.53 (1.22–4.66) 3.52 (1.84–5.26) 2.84 (1.38–4.89)
Histological grade   1.000   0.076   1.000
  1 1.00 1.00 1.00 1.00
  2 1.12 (0.63–2.57) 1.36 (0.87–2.84) 1.32 (1.13–3.37)   0.039 1.05 (0.75–1.97)
  3 5.23 (2.74–9.16) <0.001 3.72 (2.97–7.42) <0.001 6.21 (2.06–10.26) <0.001 4.34 (2.42–8.16) <0.001
Necrosis   0.019   0.042 <0.001   0.008
  Minimal or absent 1.00 1.00 1.00 1.00
  Marked 2.53 (1.10–4.13) 1.93 (1.33–4.16) 3.54 (1.97–5.40) 2.83 (1.46–3.99)
Ki67   1.000   1.000   0.032   1.000
  ≤30% 1.00 1.00 1.00 1.00
  >30% 1.17 (0.46–1.95) 0.92 (0.67–1.76) 1.76 (1.12–3,23) 1.13 (0.82–1.96)
Adjuvant chemotherapy   0.084 <0.001   0.803   0.486
  Not 1.00 1.00 1.00 1.00
  Yes 0.52 (0.21–0.94) 0.18 (0.09–0.65) 0.92 (0.58–1.42) 1.87 (0.96–4.86)

TNBC, triple-negative breast cancer; AR, androgen receptor; HR, hazard ratio; CI, confidence interval.

Cox regression analysis to estimate adjusted hazard ratios of breast cancer subtypes.

A, Cox regression analysis of all 1646 cases
Relapse-free survival Breast cancer-specific survival
Subtypes HR (95% CI) P-value HR (95% CI) P-value
IHC-Luminal A 1.00 1.00
IHC-HER2 2.96 (1.23–4.87) <0.001 3.13 (2.28–5.07) <0.001
IHC-TNBC 2.04 (1.11–4.38) 0.017 2.15 (1.43–4.16) 0.008
IHC-TN/BL 2.85 (1.18–5.02) <0.001 2.98 (1.38–6.10) <0.001
IHC-TN/AR+ 1.12 (0.87–1.68) 0.541 1.38 (0.67–2.14) 0.204
IHC-TN/CD44+CD24−/low 1.78 (1.07–3.20) 0.073 1.86 (1.18–3.75) 0.052
IHC-TN/unassigned 1.26 (1.11–2.45) 0.296 1.43 (1.06–2.82) 0.187
B, Cox regression analysis of 1360 cases treated with adjuvant chemotherapy.
Relapse-free survival Breast cancer-specific survival
Subtypes HR (95% CI) P-value HR (95% CI) P-value
IHC-Luminal A 1.00 1.00
IHC-HER2 2.61 (1.24–4.78) <0.001 2.72 (1.52–5.12) <0.001
IHC-TNBC 1.93 (1.13–3.34) 0.031 2.11 (1.28–3.84) 0.019
IHC-TN/BL 1.89 (1.17–3.96) 0.048 1.93 (1.21–4.09) 0.028
IHC-TN/AR+ 1.09 (0.45–1.56) 0.622 1.13 (0.62–2.89) 0.574
IHC-TN/CD44+CD24−/low 2.17 (0.76–2.74) 0.006 2.30 (0.95–2.84) 0.003
IHC-TN/unassigned 1.14 (0.45–2.35) 0.507 1.31 (0.61–2.72) 0.232
C, Cox regression analysis of 286 cases treated without chemotherapy.
Relapse-free survival Breast cancer-specific survival
Subtypes HR (95% CI) P-value HR (95% CI) P-value
IHC-Luminal A 1.00 1.00
IHC-HER2 3.32 (1.32–5.14) <0.001 3.48 (1.15–5.54) <0.001
IHC-TNBC 2.19 (1.11–4.98) 0.002 2.25 (1.08–5.11) <0.001
IHC-TN/BL 3.64 (1.86–7.65) <0.001 3.81 (1.98–6.32) <0.001
IHC-TN/AR+ 1.25 (0.76–2.24) 0.287 1.53 (0.68–1.98) 0.124
IHC-TN/CD44+CD24−/low 1.68 (1.14–3.07) 0.115 1.72 (0.88–2.74) 0.092
IHC-TN/unassigned 1.37 (0.64–2.73) 0.196 1.48 (0.49–2.64) 0.163

HR, hazard ratio; CI, confidence interval; IHC, immunohistochemistry; HER2, human epidermal growth factor-2; TNBC, triple-negative breast cancer; BL, basal-like; AR, androgen receptor.

Correlation between the triple-negative and non-triple negative breast cancer immunohistochemistry subtypes.

BL/TN BL/TN CD44+ CD24−/low/TN CD44+ CD24−/low/non-TN AR+/TN Luminal AR+/TN HER2
Variables n=83 n=34 P-value n=39 n=36 P-value n=18 n=965 P-value n=18 n=344 P-value
Age 0.834 0.926 0.818 0.073
  ≤50 52 22 18 17   6 347   6 189
  >50 31 12 21 19 12 618 12 155
Family history 0.575 0.775 0.924
  No 76 30 35 33 17 896 17 323
  Yes   7   4   4   3   1   69   1   21
Histological type
  Invasive ductal carcinoma 63 21 14 15   6 872   6 319
  Invasive lobular carcinoma   2   3   1   2   1   49   1   11
  Medullary carcinoma 11   6   2   0   0   12   0   7
  Metaplastic carcinoma   3   1 19 18   0   10   0   0
  Apocrine carcinoma   2   0   0   0 11   14 11   0
  Others   2   3   3   1   0   8   0   7
Pathological tumor size 0.790 0.378 0.031
  pT1 24   9 18 13 10 480 10 107
  pT2-3 59 25 21 23   8 485   8 237
Histological grade 0.764 0.836 0.561 0.019
  1   3   2   7   5   9 363   9   74
  2 12   6 11 12   6 396   6 166
  3 68 26 21 19   3 206   3 104
Lymph node status 0.609 0.345 0.710 0.318
  Negative 47 21 23 25 12 602 12 188
  Positive 36 13 16 11   6 363   6 156
Lymphovascular invasion 0.787 0.798 0.964   0.808
  Absent 63 25 26 21 16 861 16 299
  Present 20   9 13 15   2 104   2   45
Necrosis 0.553 0.680 0.424   0.145
  Minimal or absent 24   8 22 22 15 725 15 230
  Marked 59 26 17 14   3 240   3 114
Ki67 0.374 0.711 0.489   0.004
  ≤30% 29   9 19 16 14 678 14 149
  >30% 54 25 20 20   4 287   4 195
EGFR 0.728 0.701 0.701 <0.001
  Negative 41 18 30 29   8 473   8 281
  Positive 42 16   9   7 10 492 10   63
E-cadherin 0.321 0.192 0.621   0.499
  Negative 38 19 37 31   4 265   4 102
  Positive 45 15   2   5 14 700 14 242
Vimentin 0.650 0.261 0.596   0.747
  Negative 55 24   4   7 15 754 15 296
  Positive 28 10 35 29   3 211   3   48
Claudin 3 0.118 0.611 0.906   0.898
  Negative 10   8 36 32   2 116   2   35
  Positive 73 26   3   4 16 849 16 309
Claudin 4 0.318 0.834 0.647   0.646
  Negative   9   6 29 26   1   83   1   12
  Positive 74 28 10 10 17 882 17 332
Claudin 7 0.827 0.233 0.771   0.458
  Negative 11   4 28 30   1   71   1   9
  Positive 72 30 11   6 17 894 17 335
RFS event 0.928 0.602 0.714 0.151
  No 51 22 26 25 15 857 15 231
  Yes 32 12 13 11   3 108   3 113
Mean survival time 75.8 77.7 84.7 86.1 96.3 103.2 96.3 79.3
95% CI 59.9–88.4 62.8–91.4 73.4–94.2 75.6–96.6 84.0–105.7 93.3–109.2 84.0–105.7 60.5–93.6

BL, basal-like; TN, triple-negative; AR, androgen receptor, HER2, human epidermal growth factor-2; RFS relapse free survival; CI, confidence interval.